

References

1. Global strategy for prevention, diagnosis and management of COPD: 2024 report. 2024 GOLD Report - Global Initiative for Chronic Obstructive Lung Disease - GOLD (goldcopd.org)
2. Fu Y, Mason A, Boland AC, et al. Palliative care needs and integration of palliative care support in COPD: a qualitative study. *Chest* 2021; 159: 2222–2232.
3. Sullivan J et al. National and State estimates of COPD morbidity and mortality – United States 2014-2015. *Chronic Obstr Pulm Dis* 2018. Oct 12;5(4):324-333. doi: 10.15326/jcopdf.5.4.2018.0157
4. Vespasiani-Gentilucci U, Pedone C, Muley-Vilamu M et al. The Pharmacological treatment of chronic co-morbidities in COPD: mind the gap! *Pulmonary Pharmacology and Therapeutics*. 2018;51:48-58.
5. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med* 2010; 363: 1128–1138.
6. Han MK, Agustí A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. *Am J Respir Crit Care Med* 2010; 182: 598–604.
7. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. *N Engl J Med* 2011; 365: 1184–1192.
8. Patalano F, Banerji D, D’Andrea P, et al. Addressing unmet needs in the treatment of COPD. *European Respiratory Review* 2014 23: 333-344; DOI: 10.1183/09059180.00004014
9. Miravittles M, Soler-Cataluña JJ, Calle M, et al. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. *Eur Respir J* 2013; 41: 1252–1256.
10. Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. *PLoS One* 2012; 7: e37483.
11. Gore JM, Brophy CJ, Greenstone MA (2000) How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. *Thorax* 55: 1000–1006.
12. Habraken JM, Willems DL, De Kort SJ, Bindels PJE (2007) Health care needs in end-stage COPD: A structured literature review. *Patient Educ Couns* 68: 121–130.
13. Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. *Respir Med* 2012; 106: 989–997.

14. Small M, Broomfield S, Higgins V. Quantification and treatment patterns of real-world patients classified by the GOLD 2011 strategy. *Eur Respir J* 2012; 40: Suppl. 56, 524s.
15. Coultas DB, Mapel D, Gagnon R, et al. The health impact of undiagnosed airflow obstruction in a national sample of United States adults. *Am J Respir Crit Care Med* 2001; 164: 372–377.
16. Crockett AJ, Cranston JM, Moss JR, Alpers JH. The MOS SF-36 health survey questionnaire in severe chronic airflow limitation: comparison with the Nottingham health profile. *Qual Life Res* 1996;5:330-8.
17. Koskela, J., Kilpeläinen, M., Kupiainen, H. et al. Co-morbidities are the key nominators of the health related quality of life in mild and moderate COPD. *BMC Pulm Med* 14, 102 (2014). <https://doi.org/10.1186/1471-2466-14-102>
18. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. *N Engl J Med*. 2009;360(14):1418–28.
19. Mowls DS, Cheruvu VK, Schilz R, Zullo MD. COPD in a nationally representative sample: sociodemographic factors and co-morbidity, diagnosis method, and healthcare utilization. *COPD*. 2015;12(1):96–103.
20. Goto T, Yoshida K, Faridi MK, Camargo CA Jr, Hasegawa K. Contribution of social factors to readmissions within 30 days after hospitalization for COPD exacerbation. *BMC Pulm Med*. 2020;20(1):107.
21. Nurmatov U, Buckingham S, Kendall M, et al. Effectiveness of Holistic Interventions for People with Severe Chronic Obstructive Pulmonary Disease: Systematic Review of Controlled Clinical Trials *Plos One* 2010; 7(10): e46433. doi:10.1371/journal.pone.0046433
22. Hillas, G., Perlikos, F., Tsiligianni, I., & Tzanakis, N. (2015). Managing comorbidities in COPD. *International Journal of Chronic Obstructive Pulmonary Disease*, 10, 95–109. <https://doi.org/10.2147/COPD.S54473>
23. Coultas D, Jenn F, Bethany B, et al. A randomised trial of two types of nurse-assisted home care for patients with COPD. *Chest* 2005; 4(128):2017-2024. <https://doi.org/10.1378/chest.128.4.2017>
24. Hermiz O, Comino E, Marks G et al. Randomised controlled trial of home based care of patients with chronic obstructive pulmonary disease. *BMJ* 2002;325:938.
25. Gravit JH, Al-Rawas OA, Cotton MM, Flanigan U, Irwin A, Stevenson RD. Home treatment of exacerbations of chronic obstructive pulmonary disease by an acute respiratory assessment service. *Lancet* 1998;351:1853-5.

26. Strijbos JH, Postma DS, van Altena R, Gimeno F, Koeter GH. A comparison between an outpatient hospital based pulmonary rehabilitation program and a home care pulmonary rehabilitation program in patients with COPD: a follow-up of 18 months. *Chest* 1996;109:366-72.
27. Kaffash J. GPs vote for home visits to be removed from contract. *Pulse* 2019; 22 Nov: <http://www.pulsetoday.co.uk/news/gps-vote-for-home-visits-to-be-removed-from-contract/20039743.article> (accessed 28 Apr 2020)
28. Cope LC, Abuzour AS, Tully MP. Nonmedical prescribing: where are we now? *Ther Adv Drug Saf*, 7 (2016), pp. 165-172
29. Department of Health. Pharmacist Independent Prescribing FAQ: Department of Health (2010) http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Healthcare/Medicinespharmacyandindustry/Prescriptions/TheNon-MedicalPrescribingProgramme/Independentpharmacistprescribing/DH_4133943
30. Lowrie, R., McPherson, A., Mair, FS et al. Holistic health and social care outreach for people experiencing homelessness with recent non-fatal overdose in Glasgow, Scotland: the Pharmacist and third sector Homeless charity worker Outreach Engagement Non-medical Independent prescriber Rx (PHOENIX) pilot randomised controlled trial. *BMJ Public Health* 2024 2: p. e000219-e000219. <https://bmjpublichealth.bmj.com/content/2/1/e000219>
31. Hunt V, Anderson D, Lowrie R, Montgomery Sardar C, Ballantyne S, Bryson G, Kyle J, Hanlon P. A non-randomised controlled pilot study of clinical pharmacist collaborative intervention for community dwelling patients with COPD. *npj Primary Care Respiratory Medicine* 2018;28:38. doi: 10.1038/s41533-018-0105-7
32. Foot H, Scott I, Sturman N et al. Impact of pharmacist and physician collaborations in primary care on reducing readmission to hospital: a systematic review and meta-analysis. *Research in Social and Administrative Pharmacy*. 2022;18:2922-2943.
33. Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM et al. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. *BMJ* 2021. <http://dx.doi.org/10.1136/bmj.n2061>
34. Zhong, H., Ni, XJ., Cui, M. et al. Evaluation of pharmacist care for patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Int J Clin Pharm* 36, 1230–1240 (2014). <https://doi.org/10.1007/s11096-014-0024-9>

35. Abrams R., Br J Gen Pract 2020; DOI: <https://doi.org/10.3399/bjgp20X710153>
36. Bestall JC , PaulEA, GarrodR, GarnhamR, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54:758-761
37. Hoffmann TC, Glasziou PP, Boutron I, Milne R et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ 2014;348:g1687 doi: 10.1136/bmj.g1687
38. Taskforce on Medicines Partnership, The National Collaborative Medicines Management Services programme. Room for review – a guide to medication review: the agenda for patients, practitioners and managers. 2002.
39. Eton DT, Yost KJ, Lai JS, et al. Development and validation of the patient experience with treatment and self-management (PETS): a patient-reported measure of treatment burden. Qual Life Res 2017; 26:489–503
40. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011 Dec;20(10):1727-1736
41. Jones PW, Harding G, Berry P, Development and first validation of the COPD assessment test. Eur Respir J 2009 Sep; 34(3):648–654
42. Kroenke K, Spitzer RL, Williams JB, Low B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics 2009; 50(6): 613-21.
43. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good clinical practice. J Eval Clini Pract 2004; 10(2):307-312.
44. Scottish health service costs - Costs Book 2020 (April 2019 to March 2020) - Scottish health service costs - Publications - Public Health Scotland. Accessed June 28, 2024. <https://publichealthscotland.scot/publications/scottish-health-service-costs/scottish-health-service-costs-costs-book-2020-april-2019-to-march-2020/>
45. Personal Social Services Research Unit and the Centre for Health Economics. Unit costs of health and social care programme. 2022. University of York and University of Kent.
46. <https://publichealthscotland.scot/publications/scottish-health-service-costs/scottish-health-service-costs-costs-book-2020-april-2019-to-march-2020/>
- 47 <https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l>

48. Van Hout B, Janssen MF, Feng YS et al. Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets. *Value in Health* 2012; 15(5):708-715.
[https://www.valueinhealthjournal.com/article/S1098-3015\(12\)00058-7/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301512000587%3Fshowall%3Dtrue](https://www.valueinhealthjournal.com/article/S1098-3015(12)00058-7/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301512000587%3Fshowall%3Dtrue)
49. May C., Finch T. Implementing, embedding, and integrating practices: An outline of Normalization Process Theory. *Sociology*. 2009: 43(3), 535–554
50. May C, Cummings A, Girling M et al. Using normalisation process theory in feasibility studies and process evaluations of complex healthcare interventions: a systematic review. *Implementation Science* 2018;80 (13).
51. Eton D, Yost K, Lai J-s, Ridgeway J, Egginton J, Rosedahl J, et al. Development and validation of the Patient Experience with Treatment and Self-management (PETS): a patient-reported measure of treatment burden. *Quality of Life Research*. 2017;26.
51. Rogers EA, Abi H, Linzer M, Eton DT. Treatment Burden in People with Hypertension is Correlated with Patient Experience with Self-Management. *J Am Board Fam Med*. 2021;34(6):1243-5.
52. Lee MK, St Sauver JL, Anderson RT, Linzer M, Eton DT. Confirmatory Factor Analyses and Differential Item Functioning of the Patient Experience with Treatment and Self-Management (PETS vs. 2.0): A Measure of Treatment Burden. *Patient Relat Outcome Meas*. 2020;11:249-63.
53. Eton D, Egginton J, Ridgeway J, Odell L, May C, Montori VM. Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study. *Patient Relat Outcome Meas* 2012;3:39-49.47.
54. <https://www.heraldscotland.com/news/national/uk-today/23156157.royal-mail-strikes-december-2021-postal-strikes/>
55. Nordfonn OK, Morken IM, Bru LE, Larsen AI, Husebø AML. Burden of treatment in patients with chronic heart failure - A cross-sectional study. *Heart Lung*. 2021;50(3):369-74.
56. Ibrahim K, Cox NJ, Stevenson JM, Lim S et al. A systematic review of the evidence for deprescribing interventions among older people living with frailty. *BMC Geriatrics* 2021; 21 (258): <https://doi.org/10.1186/s12877-021-02208-8>

57. Omuya H, Nickel C, Wilson P et al. A systematic review of randomised-controlled trials on deprescribing outcomes in older adults with polypharmacy. *Int J Pharm Pract.* 2023; 30;31(4):349-368. <https://pubmed.ncbi.nlm.nih.gov/37155330/>
58. Traver GA. Measures of symptoms of life quality to predict emergent use of institutional health care resources in COPD. *Heart Lung* 1998;17:689-97
59. Rutten-van Molken M, Oostenbrink JB, Tashkin D, Burkart D, Brigitta M. Does Quality of life of COPD patients as measured by the generic Euroqol five dimension questionnaire differentiate between COPD severity stages? *Chest.* 2006;4(130):1117-1128.
60. Hvidberg MF, Hernandez Alava M. Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA. *Pharmacoeconomics.* 2023; 41(10): 1287–1388.
61. Mujica-Mota RE, Roberts M, Abel G, et al. Common patterns of morbidity and multimorbidity and their impact on health-related quality of life: evidence from a national survey. *Quality of Life Research.* 2015;24(4):909-918. doi:10.1007/S11136-014-0820-7/FIGURES/4
62. Barnett K, Mercer S, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for healthcare, research and medical education: a cross sectional study. *The Lancet* 2012;380:37-43.
63. Punekar YS, Landis SH, Wurst K, Le H. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care. *Respir Res.* 2015;16(1):1-10.
64. Suhaj A, Manu MK, Unnikrishnan MK, Vijayanarayana K, Mallikarjuna Rao C. Effectiveness of clinical pharmacist intervention on health-related quality of life in chronic obstructive pulmonary disorder patients - a randomized controlled study. *J Clin Pharm Ther.* 2016 Feb;41(1):78-83.
65. Morrow G, Hickok J, Burish T. Behavioral aspects of clinical trials: an integrated framework from behaviour theory. *Cancer* 1994; 74 : 2676–82
66. Brintall-Karabelas J, Sung S, Pao M et al. Improving recruitment in clinical trials: why eligible participants decline. *Journal of Empirical Research on Human Research Ethics.* 2011. <https://doi.org/10.1525/jer.2011.6.1.69>